Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis

[1]  T. Todenhöfer,et al.  Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C‐reactive protein and standard pathological risk factors: the TNR‐C score , 2011, BJU international.

[2]  Kazutaka Saito,et al.  C-reactive protein as a biomarker for urological cancers , 2011, Nature Reviews Urology.

[3]  K. Kihara,et al.  A novel repeat biopsy nomogram based on three-dimensional extended biopsy. , 2011, Urology.

[4]  M. Kattan,et al.  Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test. , 2010, The Journal of urology.

[5]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Haese*,et al.  Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. , 2010, European urology.

[7]  Andrew J Vickers,et al.  Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. , 2010, Seminars in oncology.

[8]  田所 学 Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy , 2010 .

[9]  D. McMillan,et al.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.

[10]  M. Nieto,et al.  Inflammation and EMT: an alliance towards organ fibrosis and cancer progression , 2009, EMBO molecular medicine.

[11]  M. Agerbaek,et al.  Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy , 2009, Acta oncologica.

[12]  飯村 康正 Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification : the TNM-C score , 2009 .

[13]  Elena B. Elkin,et al.  Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers , 2008, BMC Medical Informatics Decis. Mak..

[14]  K. Kihara,et al.  Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. , 2008, The Journal of urology.

[15]  Shahrokh F. Shariat,et al.  Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature , 2008, Clinical Cancer Research.

[16]  K. Kihara,et al.  C‐reactive protein level predicts prognosis in patients with muscle‐invasive bladder cancer treated with chemoradiotherapy , 2008, BJU international.

[17]  P. Malmström WHY HAS THE SURVIVAL OF PATIENTS WITH BLADDER CANCER NOT IMPROVED? , 2008, BJU international.

[18]  K. Kihara,et al.  The impact of preoperative serum C‐reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically , 2007, BJU international.

[19]  D. McMillan,et al.  Evaluation of an inflammation‐based prognostic score in patients with metastatic renal cancer , 2006, Cancer.

[20]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. C. Chen,et al.  The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. , 1985, Statistics in medicine.

[24]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.